Prime Medicine (PRME.US) was first covered by HC Wainwright & Co. with a buy rating, with a target price of $10.00.
Prime Medicine Analyst Ratings
HC Wainwright & Co. Initiates Coverage On Prime Medicine With Buy Rating, Announces Price Target of $10
Citi: Raised the Prime Medicine (PRME.US) rating from neutral to buy, with a target price of $10.00.
Prime Medicine Analyst Ratings
Citigroup Upgrades Prime Medicine at Buy From Neutral With $10 Price Target
Komo: Maintaining the Prime Medicine (PRME.US) rating, adjusted from an increase in holdings to an increase in holdings rating, and the target price was adjusted from $16.00 to $15.00.
Buy Rating Affirmed for Prime Medicine, Inc. on FDA Trial Approval and Strong Financials
Prime Medicine Analyst Ratings
Buy Rating Affirmed for Prime Medicine, Inc. on Robust Preclinical Data and Prime Editing Technology Prospects
Jefferies Investment Bank: Assuming the Prime Medicine (PRME.US) rating, adjusted from buy to buy rating, the target price was adjusted from $23.00 to $15.00.
Prime Medicine Analyst Ratings
Jefferies Issues a Buy Rating on Prime Medicine, Inc. (PRME)
Buy Rating Affirmed for Prime Medicine, Inc. on Strong Preclinical Data and Promising Clinical Outlook
Wedbush: Reiterates Prime Medicine's (PRME.US) rating and adjusted from superior to superior market rating, with a target price of $12.00.
Prime Medicine Analyst Ratings
Wedbush Reiterates Outperform on Prime Medicine, Maintains $12 Price Target
Buy Rating Affirmed for Prime Medicine, Inc. on Groundbreaking Genetic Editing Platform and Strategic Progress
Prime Medicine (PRME.US) was first covered by Chardan Capital, giving it a buy rating, with a target price of $17.00.
Prime Medicine Analyst Ratings